Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
O14933
UPID:
UB2L6_HUMAN
Alternative names:
E2 ubiquitin-conjugating enzyme L6; Retinoic acid-induced gene B protein; UbcH8; Ubiquitin carrier protein L6; Ubiquitin-protein ligase L6
Alternative UPACC:
O14933; A6NDM6; A8MY53; Q8N5D8; Q9UEZ0
Background:
Ubiquitin/ISG15-conjugating enzyme E2 L6, known by alternative names such as E2 ubiquitin-conjugating enzyme L6 and UbcH8, plays a crucial role in protein regulation. It catalyzes the covalent attachment of ubiquitin or ISG15 to other proteins, including the E6/E6-AP-induced ubiquitination of p53/TP53 and promotes the ubiquitination and subsequent proteasomal degradation of FLT3.
Therapeutic significance:
Understanding the role of Ubiquitin/ISG15-conjugating enzyme E2 L6 could open doors to potential therapeutic strategies.